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ABSTRACT 
Objective: The primary goal of the present work was to formulate and evaluate self-nano emulsifying drug delivery systems (SNEDDS) of ramipril 
in order to improve the solubility of this highly lipophilic antihypertensive drug. 
Methods: SNEDDS are generally liquid form preparations obtained by homogeneously mixing drug substance with oils, surfactants and co-
surfactants using cyclomixer. Based on solubility studies Capmul PG8 NF, Gelucire 44/14 and Transcutol P were selected as oil, surfactant and co-
surfactant respectively in order to prepare SNEDDS. Nine different SNEDDS formulations were prepared and subjected to various evaluation tests in 
order to obtain optimized SNEDDS formulation.  
Results: The SNEDDS formulations with 16.5-24.75 % of oil, 24.75-68.75 % of surfactant and 12.375-41.25 % of co-surfactant formed 
thermodynamically stable emulsion with droplet size ranging from 22.6-188.8 nm. Finally, out of 9 different SNEDDS formulations, SN9 formulation 
was optimized containing 16.5 % of oil, 68.75 % of surfactant and 13.75 % of co-surfactant as it formed a thermodynamically stable emulsion with 
least globule size (22.6 nm) and without any drug precipitation or phase separation. 
Conclusion: Finally, stable, optimized SNEDDS formulation of ramipril was successfully prepared that showed significant improvement in the rate 
of dissolution of ramipril. 
Keywords: Self nano emulsifying drug delivery system (SNEDDS), Ramipril, Emulsification time, Ternary phase diagram, Simulated Gastric Fluid (SGF). 
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INTRODUCTION 
Over decades, the oral route is considered as the easiest and most 
preferred route of drug administration for the chronic treatment 
of many diseases. Despite the unique advantages of oral drug 
delivery, the majority of prospective and existing drug molecules 
pose a challenge to the pharmaceutical scientist limiting their 
potential uses and increasing the difficulty of formulating low 
bioavailable products [1]. There are several constraints 
responsible for this, but a particularly widespread problem is poor 
absorption due to slow and/or incomplete drug dissolution in the 
lumen of the gastrointestinal tract and systemic metabolism by the 
gut wall and hepatic enzymes [2, 3]. In this case, improved 
bioavailability can be achieved by the use of delivery systems 
which can enhance the rate and/or the extent of drug solubilizing 
into aqueous intestinal fluids. 
Drugs belonging to BCS class II and IV have motivated the 
formulators for the development of drug delivery technologies to 
overcome the difficulty in their solubilization by either chemical or 
mechanical modification of the environment surrounding the drug 
substance, or physically altering the macromolecular characteristics 
of aggregated drug particles. Various traditional approaches for 
solubility enhancement include micronization, solid dispersions and 
inclusion complexes [4-7]. In the recent past, colloidal carriers like 
solid-lipid nanoparticles [8, 9], also lipid and surfactant based 
systems such as lipid nanocapsules [10, 11], nanoemulsions [12, 13], 
microemulsions [14, 15] and nano vesicular systems such as 
liposome [16, 17] or noisome [18] are being explored for oral 
delivery of drugs. Apart from them recently, self-nano emulsifying 
drug delivery systems (SNEDDS) have shown great assurance for 
enhancing bioavailability of poorly soluble compounds such as 
vinpocetine, carvedilol, zaleplon, repaglitinide etc. 
SEDDS (self-emulsifying drug delivery systems) belong to lipid-
based formulations and has proved to be promising carriers for 
improving the drug solubility and dissolution rate thus facilitating 
improved oral absorption and bioavailability of poorly water-soluble 
drugs. SEDDS are isotropic mixtures comprising of oil, surfactant, co-
surfactant, drug substance (API) and sometimes contain co-solvents 
which emulsify spontaneously upon mild agitation and upon dilution 
with aqueous media to produce a fine oil-in-water emulsion. 
Whereas, SNEDDS are defined as self-nano emulsifying drug delivery 
system in which the globule size of formed emulsion ranges in a few 
nanometers(<50 nm). They readily spread in the GIT motility 
(stomach and intestine) that provide the agitation necessary for self-
emulsification. The emulsification time of SEDDS, size of globules 
formed and the stability of the resultant emulsion, when introduced 
into water with mild agitation not only depends on the type of oil, 
surfactant and co-surfactant combination but also the weight 
percentage of oil and surfactant/co-surfactant mixture, is also 
equally important [19]. Furthermore, the commercialization of few 
SEDDS like Fortovase®(saquinavir), Norvir® (ritonavir) and 
Neoral®(cyclosporine) established interest in the commercial 
viability of using SEDDS as a delivery strategy [20].  
Ramipril {(2S, 3aS, 6aS)-1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-
phenylpropyl] amino]-1-oxopropyl] octahydrocyclopenta [b] 
pyrrole-2-carboxylic acid}, a potent antihypertensive drug, 
belonging to the category of ACE inhibitor is widely used in the 
treatment of high blood pressure and congestive heart failure. 
Ramipril is highly lipophilic [log P (octanol/water), 3.32)], poorly 
water soluble (3.5 mg/l) drug belonging to BCS Class II. Ramipril, 
being poorly water soluble resulted in erratic absorption in GIT 
which further lead to poor bioavailability (about 28 %). It also 
showed high first pass metabolism. Hence, increasing the aqueous 
solubility and dissolution of ramipril in GIT is of therapeutic 
importance. The main intention behind choosing SNEDDS 
formulation for ramipril drug was that lipid-based formulations 
enhance the solubility of lipophilic drugs that may further enhance 
the dissolution rate and absorption in the GIT. Hence, the main 
objective of current research work was to develop SNEDDS of 
ramipril in order to enhance the solubility of the drug.  
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MATERIALS AND METHODS 
Materials 
Ramipril was a generous gift sample from Ranbaxy Laboratories, 
Dewas, India. Transcutol-P, Labrafil M1944CS, Labrafil M2125CS, 
Gelucire 44/14, Capryol 90, Labrasol and Maisine 
Methods 
were obtained as 
gift samples from Gatteffose, France. Captex-355, Capmul PG 8 NF, 
Capmul MCM C8, Acconon E, Caprol Micro Express blend were kind 
gift samples from ABITEC Corporations, Cleveland, USA. Purified 
soybean oil was obtained from Lipoid, Germany. Tween 80 was 
supplied by Merck, Mumbai, India. TPGS-E was supplied by BASF 
Corporation, U. S. A and Cremophor EL was provided by BASF, 
Mumbai. All other chemicals used were of analytical grade. 
Solubility studies 
The solubility of ramipril in various vehicles like oils, surfactants 
and co-surfactants were determined by addition of an excess 
amount of ramipril to a glass vial containing 2 ml of the selected 
vehicle. The contents were vortexed using a cyclomixer until drug 
completely dissolved in the vehicle at 37 °C, then kept in a rotary 
shaker (Remi equipment, Mumbai, India) and constantly agitated 
at room temperature for 48h. After reaching equilibrium, samples 
were centrifuged at 10,000 rpm for 15 min and then the 
supernatant solution (100 µl) was suitably diluted with methanol. 
The amount of ramipril was quantified using UV-VIS spectro-
photometer at 210 nm. 
Preparation of SNEDDS  
SNEDDS formulations were prepared by dispersing ramipril into the 
mixture of oil, surfactants and co-surfactants those selected based 
on solubility studies. The contents were initially mixed by gentle 
stirring and then subjected to vortex mixing at 37 °C using 
cyclomixer until the homogenous isotropic mixture was obtained. 
The obtained SNEDDS were kept at room temperature until used. 
Evaluation of SNEDDS 
Evaluation of self-emulsification time and stability  
Self-emulsifying properties of SNEDDS formulations were 
performed by visual assessment [21]. For this, about 100 µl of 
SNEDDS formulation was added dropwise to a beaker containing 
about 300 ml SGF at 37 °C which was kept under continuous stirring 
(~100 rpm) using magnetic stirrer. The time taken for the emulsion 
formation for each formulation was recorded. In order to determine 
the stability of SNEDDS, the formed emulsion was stored at 37 °C 
and observed for phase separation and precipitation of the drug, if 
any for 48 h [22]. The stable SNEDDS formulations were selected 
and subjected to further characterization. 
Thermodynamic stability studies 
The formulations were subjected to heating-cooling, centrifugation, 
and freeze-thaw cycle, where the physical appearances of the 
formulations were observed at the end of each testing. In heating 
cooling, all nine formulations were heated at 45 °C and then cooled to 
4 °C, with the duration of 24 h at each temperature, for 2 cycles. Then, 
formulations which passed the heating-cooling cycles were subjected 
to centrifugation at 3500 rpm (temp 18 °C) for 15 min using REMI 
Cooling Centrifuge, and the extent of phase separation was monitored. 
[23]. Finally, only formulations which passed the previous two steps 
were stored at alternating temperature of-21 °C and 25 °C, with 
storage at each temperature for not less than 48 h was done for the 
formulations using REMI Quick Freezer, for 2 cycles [23]. 
Cloud point measurement  
The cloud point measurement was carried out for the formulations 
as reported earlier [24]. About 50 μl of stable SNEDDS was added to 
300 ml of SGF and emulsion was obtained in vitro by using magnetic 
stirrer. From which, 10 ml of the emulsion sample was taken and 
heated with a gradual rise in temperature. The cloud point was 
determined by visual inspection of cloudy appearance in emulsions 
at a particular temperature.  
Robustness to dilution 
SNEDDS formulations were subjected to various folds of dilution i.e. 
1:50, 1:100, 1:500 and 1:1000 with SGF (pH 1.2). The diluted 
emulsions were stored for 24 h and monitored for any physical 
changes such as precipitation or phase separation [25].  
Ternary phase diagram  
About 100μl of SNEDDS formulation was introduced into a beaker 
containing 300 ml SGF at 37 °C. The contents were mixed using magnetic 
stirrer, set at 100 rpm. The existence of SNEDDS that could self-emulsify 
under dilution and gentle agitation was identified from ternary phase 
diagrams of systems containing oil, surfactant, and cosurfactant. 
Precipitation of drug and phase separation was evaluated by visual 
inspection of the resultant emulsion after 24 h. The formulations 
were then categorized as clear (transparent or translucent or 
transparent with bluish tinge), unclear (turbid), stable (no 
precipitation at the end of 24 h), or unstable (showing precipitation 
within 24 h) [21]. Ternary phase diagram was constructed 
identifying the good self-emulsifying region. Ternary phase diagram 
was constructed identifying the good self-emulsifying region using 
Tri-plot v1-4 software [26]. The experiment was conducted in 
triplicate and similar observations being made between the repeats.  
Globule size and zeta potential analysis 
The mean globule size (z-average), zeta potential as well as the 
polydispersity index(PI) of nanoemulsions formed from stable 
SNEDDS formulations was determined by photon correlation 
spectroscopy using nanosized (Nano ZS 90, Malvern instruments, UK). 
Before analysis, each formulation was diluted to a suitable 
concentration with filtered double distilled water. Size analysis was 
performed at 25 °C with an angle of detection of 90 °. All studies were 
repeated three times and the average values obtained were used. 
In vitro dissolution studies 
Dissolution studies were carried out using USP Type II Dissolution 
Apparatus (paddle type) (Electrolab, TD L8, Mumbai, India) in 900 ml 
of SGF (pH 1.2) without enzyme, the temperature at 37±0.5°C and 
paddle rotation of 50 rpm. 250 mg of formulation containing 2.5 mg of 
ramipril (equivalent to a single dose) was encapsulated and then 
installed to the dissolution medium. At predetermined time intervals 5 
ml of sample was withdrawn and replenished with fresh dissolution 
medium (SGF) to maintain a constant volume. The samples were 
analyzed spectrophotometrically at 210 nm to detect the amount of 
drug released at each sampling point. The in vitro drug release data 
was analyzed by one-way analysis of variance (ANNOVA). 
RESULTS AND DISCUSSION 
Solubility Studies 
The solubility of ramipril was carried out in various oils, surfactants, 
co-surfactants and among the excipients screened Capmul PG8 NF, 
Gelucire 44/14 and Transcutol-P have shown the highest solubility 
and hence they were selected as oil, surfactant and co-surfactant 
respectively. All the studies were conducted in triplicate, and the 
mean of three measurements was recorded. The results were 
depicted in fig. 1. 
Preparation of SNEDDS  
The selection of oil, surfactant and the co-surfactant mixture is based on 
the solvent properties of the vehicle that should allow the drug in 
solution. 
SNEDDS formulations were prepared using Capmul PG8 NF, Gelucire 
44/14 and Transcutol P as oil, surfactant and co-surfactant 
respectively based on solubility study results. Initially, a single dose 
of ramipril (2.5 mg) was accurately weighed and dissolved in 
calculated amount of oil, surfactant and co-surfactant in a glass vial. 
A series of self-emulsifying systems were prepared in each set with 
varying percent ratios of oil (16.5-49.5 %), surfactant (24.75–68.75 
%) and co-surfactant (8.25–41.25 %). Here nine different SNEDDS 
formulations were prepared and coded as SN1, SN2, SN3, SN4, SN5, 
SN6, SN7, SN8 and SN9 as showed in table 1.  
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Capmul PG-8 NF is chemically Propylene Glycol Monocaprylate. It is 
lipophilic in nature, having HLB value 5-6 and is generally practiced 
to create stable emulsions. Gelucire 44/14 belongs to a group of poly 
oxy glycerides. Polyoxyglycerides (also named macrogol glycerides 
by EP) are a well-established class of pharmaceutical excipients for 
enhancing solubility and bioavailability [27, 28]. 
 
 
Fig. 1: Solubility studies of ramipril in different vehicles. Mean of three measurements±SD (n=3) 
 
Table 1: Composition of ramipril SNEDDS with different ratios of oil: surfactant: co-surfactant 
SNEDDS formulation 
Code 










SN 1 1:1 1:1 123.75 61.875 61.875 2.5 
SN 2 1:3 1:1 61.875 92.8125 92.8125 2.5 
SN 3 1:5 1:1 41.25 103.125 103.125 2.5 
SN 4 1:1 3:1 123.75 92.8125 30.9375 2.5 
SN 5  1:3 3:1 61.875 139.21875 46.40625 2.5 
SN 6 1:5 3:1 41.25 154.6875 51.5625 2.5 
SN 7 1:1 5:1 123.75 103.125 20.625 2.5 
SN 8  1:3 5:1 61.875 154.6875 30.9375 2.5 
SN 9 1:5 5:1 41.25 171.875 34.375 2.5 
SNEDDS: Self nano emulsifying drug delivery system, S mix: ratio of surfactant to co-surfactant 
 
Evaluation of SNEDDS 
Evaluation of self-emulsification time and stability 
The efficiency of self-emulsifying systems will be measured from the 
rate of emulsification upon hydration with mild agitation [21]. 
Surfactant systems in SNEDDS formulation reduce the interfacial 
tension between oil and aqueous phases resulting in easy dispersion 
and formation of o/w emulsion. Self-emulsification time of all 
SNEDDS formulation formulations was shown in table 2.  
 
Table 2: Assessment of self-emulsification time of ramipril SNEDDS 
 SNEDDS formulation  Oil: s mix Self-emulsification 
time (sec) 
SN 1 1:1 44±3.0 
SN 2 1:3 36±2.0 
SN 3 1:5 30±2.0 
SN 4 1:1 26±2.0 
SN 5  1:3 21±1.0 
SN 6 1:5 18±2.0 
SN 7 1:1 15±1.0 
SN 8  1:3 12±2.0 
SN 9 1:5 8±2.0 
 Mean of three measurements±SD (n=3).  
As the oil proportion increased from SN 9 to SN 1 formulation, there 
was a decrease in the rate of emulsification and increase in 
emulsification time. The higher interfacial tension between oil and 
aqueous phase and a decrease in concentration of surfactant may be 
in charge of the increased self-emulsification time.  
The formulations SN 3, SN 6, SN 8 and SN 9 formed stable 
emulsions without any phase separation and precipitation of drug 
upon standing at room temperature for 48 h as showed in table 3. 
Hence, these formulations were treated for further 
characterization. 
 
Table 3: Results for phase separation and precipitation of drug 
from ramipril SNEDDS 
 SNEDDS formulation Phase separation Drug precipitation 
SN 1 yes No 
SN 2 yes No 
SN 3 no No 
SN 4 yes No 
SN 5  yes No 
SN 6 no No 
SN 7 yes No 
SN 8  no No 
SN 9 no No 
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Thermodynamic stability studies 
The resultant emulsions of the formulations were tested for stability 
at different temperature conditions and rpm. The emulsions were 
stable during heating and cooling cycle, centrifugation at 3500 rpm 
and alternative temperature cycles of-21 °C and+25 °C. SN 3, SN 6, 
SN 8 and SN 9 formulations did not show any phase separation and 
precipitation which indicated that they were stable at different 
temperatures and speed of centrifugation (table 4). 
 
Table 4: Results for thermodynamic stability studies of ramipril 







SN 3 P P P 
SN 6 P P P 
SN 8 P P P 
SN 9 P P P 
P=Passed 
 
Cloud point measurement 
The temperature at which cloudiness appeared was considered as 
the cloud point temperature. Higher cloud point values indicate 
higher thermal stability of emulsions formed from SNEDDS 
formulation. The cloud point is the temperature above which clarity 
of emulsion turns into turbid or unclear. In this study cloud point of 
stable formulations were found in the range of 64-72 °C (table 5).  
 
Table 5: Results for cloud point measurement of ramipril SNEDDS 
SNEDDS formulation Cloud point temperature (°C) 
SN 3 64±1.0 
SN 6  68±1.00 
SN 8 70±2.0 
SN 9 72±1.0 
Mean of three measurements±SD (n=3). 
Since both drug solubility, as well as formulation stability, will 
decrease with phase separation, the cloud point temperature of the 
formulation should be over 37 °C. Cloud points of all formulations 
were very high which indicate the stability of these SNEDDS 
formulations towards separation in the GIT temperature which is 
about 37°C. The cloud point value is affected by factors such as drug 
hydrophobicity, kind, combination, mixing ratio and amount of each 
of the oils, surfactants and co-surfactants used [24, 29]. 
Robustness to dilution  
SNEDDS formulations which were passed in previous tests were 
exposed to different folds of dilution in SGF in an attempt to mimic 
the in vivo conditions where the formulations would encounter 
gradual dilution. The resultant SNEDDS formulation was stable after 
dilution up to 50X, 100X, 500X, 1000X with SGF(pH1.2) and there 
were no signs of drug precipitation and phase separation (table 6). 
The clarity of dispersion might be due to a higher percentage of 
surfactant to oil ratio. 
Ternary phase diagram 
In order to determine the composition of oil and S mix (surfactant to 
co-surfactant) used for SNEDDS formulation, a ternary phase 
diagram was constructed, and the efficient emulsification region was 
identified. Fig. 2 illustrates the formation of a stable emulsion 
without any phase separation and precipitation of drug with SN3, 
SN6, SN8 and SN9 formulations. The emulsification time of SNEDDS 
formulations, the size of globules formed and the stability of the 
resultant emulsion when introduced into the water with mild 
agitation not only depend on the type of oil, surfactant, and co-
surfactant combination but also on the weight percentage of oil and 
surfactant/co-surfactant mixture [19]. Depending on the weight 
percentages of lipid vehicles in stable SNEDDS formulations, phase 
diagram was plotted using Triplot software. Here in these four 
stable SNEDDS formulations i.e. SN3, SN6, SN8 and SN9 weight 
percentage of oil, surfactant and co-surfactant ranges from 16.5-
24.75 %, 41.25-68.75 %, and 12.375-41.25 % respectively. Ternary 
phase diagram including oil (Capmul PG8 NF), surfactant (Gelucire 
44/14) and co-surfactant (Transcutol P) was plotted each of them 
representing an apex of the triangle. 
 
Table 6: Results for robustness to dilution of ramipril SNEDDS 
SNEDDS formulation Dilution factor 50 Dilutionfactor100 Dilution factor500  Dilutionfactor1000 
SN 3 P P P P 
SN 6 P P P P 
SN 8 P P P P 




Fig. 2: Ternary phase diagram of ramipril SNEDDS with 
different ratios of oil: surfactant: co-surfactant 
Globule size and zeta potential analysis 
Since globule size is one of the prime factors which significantly 
contribute to the absorption of the drug, the globule size and size 
distribution after self-emulsification is an important parameter that 
has to be evaluated. Of formulations from SN3 to SN9, globule size 
was significantly decreased (table 7). This resulted because of the 
concentration of surfactant increased, and that of oil decreased from 
SN3 to SN9. High surfactant levels enabled rapid dispersion of 
globules in SGF. A surfactant having hydrophilic nature (high HLB) 
assists information of O/W emulsion rapidly spreading in an 
aqueous medium. Surfactants are amphiphilic in nature & they can 
dissolve or soluble relatively high amount of hydrophobic drug 
compound. This can prevent precipitations of the drug within the GI 
lumen & for prolong the existence of drug molecules. Since droplet 
surface area is inversely proportional to diameter, smaller lipid 
droplets with their associated, greater surface area are thought to 
facilitate digestion, resulting in more lipid and uniform drug release 
and absorption [30]. 
The higher the zeta potential, greater will be the energy barrier to 
coalescence between oil globules and so higher will be the stability 
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of the obtained emulsion. Negative zeta potential values also enable 
long circulation half-life in vivo as described by Jung [31]. 
Formulation SN9 showed the least globule size with negative zeta 
potential when dispersed in SGF. Polydispersibility index (P. I) of 
SN3, SN6, SN8, SN9 formulations was below 0.3 indicating 
homogeneous dispersion. 
In vitro dissolution studies 
To understand the release behavior of ramipril from stable SNEDDS 
and pure drug, in vitro dissolution test was performed and the 
cumulative percentage of drug release profiles was depicted in fig. 3. 
The amount of ramipril released from stable SNEDDS formulation, SN9 
was 97.65±3.1 % in 60 min and was significantly higher compared to 
the pure drug (50.98±2.7) (P<0.05) and the final results were 
demonstrated in table 8. This might be because of small globule size 
and the eventually higher surface area in case of nanoemulsions 
compared to that of pure drug, which permitted faster rate of drug 
release. The reason behind this might be the use of excellent surfactant 
Gelucire 44/14 (lauroyl macro glyceride) which is good solubilizer as 
well as a wetting agent having HLB value of 14. This property 
enhanced solubility and wettability of API in vitro. Gelucire also 
possesses the property of bioavailability enhancement associated with 
improved in vivo drug solubilization which facilitates absorption [32]. 
 
Table 7: Globule size and zeta potential of ramipril SNEDDS 
SNEDDS formulation Z-average (nm)  Zeta potential (mV)   P. I  
SN 3 188.8  -4.26 0.238  
SN 6 126.7  -4.35  0.255  
SN 8 65.5 -4.48  0.278 
SN 9 22.6 -4.69 0.299 
P. I: Polydispersity Index 
 
Table 8: Cumulative % drug release of ramipril SNEDDS and pure drug 
Time (min) Pure drug  SN 3  SN 6  SN 8  SN 9 
0 0 0 0 0 0 
15 15.45±2.3 19.76±2.4 22.54±2.7 26.32±2.7 31.78±3.3 
30 26.32±2.6 30.32±2.5 35.66±2.9 42.12±2.6 51.33±3.5 
45 33.52±2.9 42.32±2.1 53.44±2.4 62.22±2.5 75.45±2.8 
60 50.98±2.7 62.12±3.1 71.32±2.3 84.45±2.9 97.65±3.1* 
Mean of three measurements±SD (n=3)., *p<0.05 indicate significant difference compared to that of pure drug. 
 
 
Fig. 3: Cumulative % drug release of ramipril SNEDDS and pure drug (mean±SD; n=3) 
 
CONCLUSION  
As per the plan of research work, stable self-nano emulsifying drug 
delivery system (SNEDDS) of ramipril was prepared successfully 
which showed improved solubility of the drug. The stable SNEDDS 
has shown good clarity, thermodynamic stability, the spontaneity of 
emulsification, robustness to dilution, high cloud point temperatures 
and good stability towards precipitation and phase separation 
throughout the examination. Out of which SNEDDS formulation (SN 
9) proved to have a high percentage release of ramipril compared to 
that of pure drug and other SNEDDS formulation. Thus finally, stable 
SNEDDS formulation, SN 9 was selected as optimized SNEDDS 
formulation which showed improved solubility of the drug. 
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